Literature DB >> 19893476

Oral lichen planus: a review.

M Carrozzo1, R Thorpe.   

Abstract

Oral lichen planus (OLP) is a common chronic inflammatory disorder thought to have a low risk of associated malignancy. A genetic predisposition linked to Th1 cytokine polymorphisms may promote the T cell-mediated immunological response to an induced antigenic change that is supposed to lead to OLP lesions. Some putative etiologic factors, mainly amalgam restorations and hepatitis C virus, have been studied in detail. The diagnosis of OLP can be made from the clinical features if they are sufficiently characteristic, but biopsy is recommended to confirm the diagnosis, exclude dysplasia and malignancy and if active treatment is required. The management of OLP is mainly aimed at controlling the symptoms and topical immunomodulators such as powerful corticosteroids and calcineurin inhibitors have been used. However, their long-term effects need to be better explored and understood. Current therapeutic data is probably still insufficient to make detailed recommendations with regard to the specific dosage, formulation, mode of delivery or length of therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19893476

Source DB:  PubMed          Journal:  Minerva Stomatol        ISSN: 0026-4970


  34 in total

1.  Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential.

Authors:  Božana Lončar-Brzak; Marko Klobučar; Irena Veliki-Dalić; Ivan Sabol; Sandra Kraljević Pavelić; Božo Krušlin; Marinka Mravak-Stipetić
Journal:  Clin Oral Investig       Date:  2017-08-04       Impact factor: 3.573

2.  The dynamics of oral lichen planus: a retrospective clinicopathological study.

Authors:  Ilana Kaplan; Yael Ventura-Sharabi; Gavriel Gal; Shlomo Calderon; Yakir Anavi
Journal:  Head Neck Pathol       Date:  2011-12-13

3.  Gustatory function and taste perception in patients with oral lichen planus and tongue involvement.

Authors:  Valerie G A Suter; Simona Negoias; Hergen Friedrich; Basile N Landis; Marco-Domenico Caversaccio; Michael M Bornstein
Journal:  Clin Oral Investig       Date:  2016-06-06       Impact factor: 3.573

Review 4.  Implant rehabilitation in patients with oral lichen planus: an overview.

Authors:  Massimo Petruzzi; Michele De Benedittis; Roberto Cortelazzi; Lucio Milillo; Alberta Lucchese; Rosario Serpico; Felice Roberto Grassi
Journal:  Clin Oral Investig       Date:  2012-03-01       Impact factor: 3.573

Review 5.  Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP.

Authors:  Alexandru Mester; Ondine Lucaciu; Lidia Ciobanu; Dragos Apostu; Aranka Ilea; Radu Septimiu Campian
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

6.  The use of topical corticosteroides in the treatment of oral lichen planus in Spain: A national survey.

Authors:  L Piñas; A García-García; M Pérez-Sayáns; R Suárez-Fernández; M-H Alkhraisat; E Anitua
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2017-05-01

7.  Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus.

Authors:  Lakshmi Mitreyi Gorugantula; Terry Rees; Jacqueline Plemons; Huey-Shys Chen; Yi-Shing Lisa Cheng
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-08

Review 8.  Green tea consumption: an alternative approach to managing oral lichen planus.

Authors:  Jing Zhang; Gang Zhou
Journal:  Inflamm Res       Date:  2012-02-10       Impact factor: 4.575

9.  Association of vdr, cyp27b1, cyp24a1 and mthfr gene polymorphisms with oral lichen planus risk.

Authors:  Bojan Kujundzic; Katarina Zeljic; Gordana Supic; Marko Magic; Dragan Stanimirovic; Vesna Ilic; Barbara Jovanovic; Zvonko Magic
Journal:  Clin Oral Investig       Date:  2015-08-26       Impact factor: 3.573

Review 10.  Oral manifestations of hepatitis C virus infection.

Authors:  Marco Carrozzo; Kara Scally
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.